Statin (cerivastatin) protects mice against sepsis-related death via reduced proinflammatory cytokines and enhanced bacterial clearance

Surgical Infections

Volumn 9, Issue 2, 2008, Pages 183-194

  Chaudhry, Mohammad Z ^a   Wang, Jiang Huai ^a   Blankson, Siobhan ^a   Redmond, H Paul ^a  

^a University College Cork and INFANT Centre   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

CERIVASTATIN; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIUM COLONY; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG EFFECT; DRUG RESPONSE; GRAM NEGATIVE SEPSIS; INFECTION PREVENTION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SALMONELLA TYPHIMURIUM; STAPHYLOCOCCUS AUREUS;

ANIMALS; DISEASE MODELS, ANIMAL; ESCHERICHIA COLI; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INTERLEUKIN-6; LIPOPOLYSACCHARIDES; MALE; MICE; PYRIDINES; SALMONELLA TYPHI; SHOCK, SEPTIC; STAPHYLOCOCCUS AUREUS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 42449120103     PISSN: 10962964     EISSN: None     Source Type: Journal    
DOI: 10.1089/sur.2006.077     Document Type: Article

References (41)

1. Bochud PY, Calandra T. Pathogenesis of sepsis: New concepts and implications for future treatment. BMJ 2003;326:262-266.
2. Freeman BD, Natanson C. Anti-inflammatory therapies in sepsis and septic shock. Expert Opin Investig Drugs 2000;9:1651-1663.
3. Angus DC, Linde-Zwirble WT, Lidicker J, et al. Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated cost of care. Crit Care Med 2001;29:1303-1310.
4. Bochud PY, Glauser MP, Calandra T. Antibiotics in sepsis. Intensive Care Med 2001;27:S33-S48.
5. Endo A, Tsujita Y, Kuroda M, et al. Inhibition of cholesterol synthesis in vitro and in vivo by ML-236A and ML-236B, competitive inhibitors of 3-hydroxy 3-glutaryl-coenzyme A reductase. Eur J Biochem 1977;77:31-36.
6. Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Science 1986;232:34-47.
7. Corsini A. Bellosta S, Baetta R, et al. New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol Ther 1999;84:413-428.
8. Albert MA, Danielson E, Rifai N, et al. Effect of statin therapy on C-reactive protein levels: The pravastatin inflammation/CRP evaluation (PRINCE): A randomized trial and cohort study. JAMA 2001;286:64-70.
9. Faggiotto A, Paoletti R. Do pleiotropic effects of statins beyond lipid alterations exist in vivo? What are they and how do they differ between statins? Curr Atheroscler Rep 2000;2:20-25.
10. Laufs U, La Fata V, Plutzky J, et al. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 1998;97:1129-1135.
11. Brandes RP, Behra A, Lebherz C, et al. Lovastatin maintains nitric oxide-but not EDHF-mediated endothelium-dependent relaxation in the hypercholestrolemic rabbit carotid artery. Atherosclerosis 1999;142:97-104.
12. Endres M, Laufs U, Huang Z, et al. Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-Co-A reductase inhibitors mediated by endothelial nitric oxide synthase. Proc Natl Acad Sci USA 1998;95:8880-8885.
13. Hernandez-Parera O, Perez-Sala D, Navarro-Antolin J, et al. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest 1998;101:2711-2719.
14. Essig M, Nguyen G, Prie D, et al. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors increase fibrinolytic activity in rat aortic endothelial cells: Role of geranylgeranylation and Rho proteins. Circ Res 1998;83:683-690.
15. Bellosta S, Bernini F, Ferri N, et al. Direct vascular effects of HMG-CoA reductase inhibitors. Atherosclerosis 1998;137:S101-S109.
16. Colli S, Eligini S, Lalli M, et al. Vastatins inhibit tissue factor in cultured human macrophages: A novel mechanism of protection against atherothrombosis. Arterioscler Thromb Vasc Biol 1997;17:265-272.
17. Muller C, Kiehl MG, van de Loo J, et al. Lovastatin induces p21WAF1/Cip1 in human vascular smooth cells: Influence on protein phosphorylation, cell cycle, induction of apoptosis, and growth inhibition. Int J Mol Med 1999;3:63-68.
18. Corsini A, Bernini F, Quarato P, et al. Non-lipid-related effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Cardiology 1996;87:458-468.
19. Vrtovsnik F, Couette S, Prie D, et al. Lovastatin-induced inhibition of renal epithelial tubular cell proliferation involves a p21ras activated, AP1-1-dependent pathway. Kidney Int 1997;52:1016-1027.
20. Farnier M, Davignon J. Current and future treatment of hyperlipidaemia: The role of statins. Am J Cardiol 1998;82:3J-10J.
21. Weitz-Schmidt G. Statins as anti-inflammatory agents. Trends Pharmacol Sci 2002;23:482-486.
22. Zhang FL, Casey PJ. Protein prenylation: Molecular mechanisms and functional consequences. Annu Rev Biochem 1996;65:241-269.
23. Almog Y, Shefer A, Novack V, et al. Prior statin therapy is associated with a decreased rate of severe sepsis. Circulation 2004;110:880-885.
24. Liappis AP, Kan VL, Rochester CG, et al. The effect of statins on mortality in patients with bacteremia. Clin Infec Dis 2001;33:1352-1357.
25. Steiner S, Speidl WS, Pleiner J, et al. Simvastatin blunts endotoxin-induced tissue factor in vivo. Circulation 2005;111:1841-1846.
26. Ando H, Takamura T, Ota T, et al. Cerivastatin improves survival of mice with lipopolysaccharide-induced sepsis. J Pharmacol Exp Ther 2000;294:1043-1046.
27. Merx MW, Liehn EA, Janssens U, et al. HMG-CoA reductase inhibitor simvastatin profoundly improves survival in murine model of sepsis. Circulation 2004;109:2560-2565.
28. Merx MW, Liehn EA, Graf J, et al. Statin treatment after onset of sepsis in a murine model improves survival. Circulation 2005;112:117-124.
29. Angus DC, Linde-Zwirble WT, Lidiker J, et al. Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001;29:1303-1310.
30. Sessler CN, Shepherd W. New concepts in sepsis. Curr Opin Crit Care 2002;5:465-472.
31. Dunzendorfer S, Rothbucher D, Schratzberger P, et al. Mevalonate-dependent inhibition of transendothelial migration and chemotaxis of human peripheral blood neutrophils by pravastatin. Circ Res 1997;81:963-969.
32. Casey PJ. Mechanism of protein prenylation and role in G protein function. Biochem Soc Trans 1995;23:161-166.
33. Kreuzer J, Bader J, Janh L, et al. Chemotaxis of the monocyte cell line U 937: Dependence on cholesterol and early mavolonate pathyway products. Athersclerosis 1991;90:203-209.
34. Kwak B, Mulhaupt F, Myit S, et al. Statins as a newly recognized type of immunomodulator. Nat Med 2000;6:1399-1402.
35. Weitz-Schmidt G, Welzenbach K, Brinkmann V, et al. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med 2001;7:687-692.
36. Chen JC, Huang KC, Wingerd B, et al. HMG-CoA reductase inhibitors induce COX-2 gene expression in murine macrophages: role of MAPK cascades and promoter elements for CREB and C/EBPbeta. Exp Cell Res 2004;301:305-319.
37. Feingold KR, Hardardottir I, Memon R, et al. Effect of endotoxin on cholesterol biosynthesis and distribution in serum lipoproteins in Syrian hamsters. J Lipid Res 1993;34:2147-2158.
38. Echtenacher B, Falk W, Mannel DN, et al. Requirement of endogenous tumor necrosis factor/cachectin for recovery from experimental peritonitis. J Immunol 1990;145:3762-3766.
39. Nakane A, Okamoto M, Asano M, et al. Endogenous gamma interferon, tumor necrosis factor, and interleukin-6 in Staphylococcus aureus infection in mice. Infect Immun 1995;63:1165-1172.
40. Eskandari MK, Bolgos G, Miller C, et al. Anti-tumor necrosis factor antibody therapy fails to prevent lethality after cecal ligation and puncture or endotoxemia. J Immunol 1992;148:2724-2730.
41. Peschon JJ, Torrance DS, Stocking KL, et al. TNF receptor-deficient mice reveal divergent roles for p55 and p75 in several models of inflammation. J Immunol 1998;160:943-952.